Correlation Between Lyxor 1 and Novo Nordisk

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Lyxor 1 and Novo Nordisk at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lyxor 1 and Novo Nordisk into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Lyxor 1 and Novo Nordisk AS, you can compare the effects of market volatilities on Lyxor 1 and Novo Nordisk and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lyxor 1 with a short position of Novo Nordisk. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lyxor 1 and Novo Nordisk.

Diversification Opportunities for Lyxor 1 and Novo Nordisk

-0.3
  Correlation Coefficient

Very good diversification

The 3 months correlation between Lyxor and Novo is -0.3. Overlapping area represents the amount of risk that can be diversified away by holding Lyxor 1 and Novo Nordisk AS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Novo Nordisk AS and Lyxor 1 is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lyxor 1 are associated (or correlated) with Novo Nordisk. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Novo Nordisk AS has no effect on the direction of Lyxor 1 i.e., Lyxor 1 and Novo Nordisk go up and down completely randomly.

Pair Corralation between Lyxor 1 and Novo Nordisk

Assuming the 90 days trading horizon Lyxor 1 is expected to generate 0.36 times more return on investment than Novo Nordisk. However, Lyxor 1 is 2.8 times less risky than Novo Nordisk. It trades about 0.13 of its potential returns per unit of risk. Novo Nordisk AS is currently generating about -0.13 per unit of risk. If you would invest  2,481  in Lyxor 1 on December 29, 2024 and sell it today you would earn a total of  204.00  from holding Lyxor 1 or generate 8.22% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Lyxor 1   vs.  Novo Nordisk AS

 Performance 
       Timeline  
Lyxor 1 

Risk-Adjusted Performance

OK

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Lyxor 1 are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite nearly unsteady basic indicators, Lyxor 1 may actually be approaching a critical reversion point that can send shares even higher in April 2025.
Novo Nordisk AS 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Novo Nordisk AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

Lyxor 1 and Novo Nordisk Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Lyxor 1 and Novo Nordisk

The main advantage of trading using opposite Lyxor 1 and Novo Nordisk positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lyxor 1 position performs unexpectedly, Novo Nordisk can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novo Nordisk will offset losses from the drop in Novo Nordisk's long position.
The idea behind Lyxor 1 and Novo Nordisk AS pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Other Complementary Tools

Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk